Waxman/Hatch Reinterpretation Underpins Change In 30-Month Stay Policy
Executive Summary
FDA's proposal to allow only one 30-month stay of approval for ANDAs hinges on a reinterpretation of Waxman/Hatch language declaring that patent holders must be notified if a generic application is amended to "include" a Paragraph IV certification
You may also be interested in...
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
FDA Chief Counsel Troy Resigns; Agency Says It Will Still Support Preemption
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said
FDA Generics Rule: Agency Will Scrutinize Paragraph III Switches, Troy Says
Generic firms that switch Paragraph III patent certifications to Paragraph IVs once the threat of a 30-month stay of approval is gone will be subject to increased scrutiny by FDA, Chief Counsel Daniel Troy said